Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

NCT03879382 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

POMES Syndrome
Relapsed and Refractory POMES Syndrome

Interventions

BIOLOGICAL: anti-CD19/BCMA CAR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]